Setback for use of novel CHD (coronary heart disease) markers
This article was originally published in Clinica
Routine screening for 19 novel coronary heart disease (CHD) risk markers, including C-reactive protein (CRP), is not warranted, a US study of over 15,000 individuals has revealed.
You may also be interested in...
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.